FMC Corp Explores Strategic Options Including Company Sale Amidst Significant Goodwill Impairment and Weak Outlook
FMC sits 38% above its 52-week low of $12.17 on elevated volume (1.9× avg).
Summary
FMC Corporation announced it is exploring strategic options, including a sale of the company, following a massive $1.356 billion goodwill impairment and reporting significantly weaker-than-expected Q4 and full-year 2025 financial results, alongside a negative 2026 outlook.
Key Events · M&A and Partnerships · FMC
-
Strategic Options Exploration
The Board of Directors has authorized the exploration of strategic options, including a potential sale of the company, to maximize shareholder value and position its assets for long-term success.
-
Massive Goodwill Impairment
The company reported a $1.356 billion non-cash goodwill impairment in Q4 2025, leading to a GAAP net loss of $1.72 billion for the quarter and $2.24 billion for the full year.
-
Weak 2025 Financial Results
FMC reported a 12% decline in Q4 2025 revenue and an 18% decline for the full year 2025. Adjusted EPS and EBITDA also saw significant decreases in both periods.
-
Negative 2026 Outlook
The company provided a weak 2026 outlook, projecting a 5% decline in full-year revenue, a 17% decline in Adjusted EBITDA, and a 41% decrease in Adjusted EPS. Q1 2026 is expected to be particularly challenging with a 58% decrease in Adjusted EBITDA.
Analysis · FMC · Industrial Applications And Services
FMC Corporation's Board of Directors has authorized the exploration of strategic options, including a potential sale of the company, to unlock shareholder value and optimize its growth and core portfolios. This significant announcement comes alongside a deeply negative financial report, including a GAAP net loss of $1.72 billion in Q4 2025 and $2.24 billion for the full year, primarily driven by a substantial $1.356 billion non-cash goodwill impairment. The impairment reflects a significant decline in the company's perceived value and future earnings potential. Furthermore, the company provided a weak 2026 outlook, projecting further declines in revenue, Adjusted EBITDA, and Adjusted EPS, with negative free cash flow. The Q1 2026 outlook is particularly challenging, showing a projected 58% decrease in Adjusted EBITDA. The strategic review, while potentially offering an exit for shareholders, is initiated from a position of financial weakness, suggesting a need for a transformative solution to address ongoing operational and market challenges, including managing the post-patent transition for Rynaxypyr® active and strengthening the balance sheet through debt reduction and asset sales like the India commercial business.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, FMC was trading at $16.79 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $12.17 to $55.21. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.